<SEC-DOCUMENT>0001493152-24-000111.txt : 20240102
<SEC-HEADER>0001493152-24-000111.hdr.sgml : 20240102
<ACCEPTANCE-DATETIME>20240102170012
ACCESSION NUMBER:		0001493152-24-000111
CONFORMED SUBMISSION TYPE:	424B3
PUBLIC DOCUMENT COUNT:		2
FILED AS OF DATE:		20240102
DATE AS OF CHANGE:		20240102

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Microbot Medical Inc.
		CENTRAL INDEX KEY:			0000883975
		STANDARD INDUSTRIAL CLASSIFICATION:	SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
		ORGANIZATION NAME:           	08 Industrial Applications and Services
		IRS NUMBER:				943078125
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		424B3
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-273207
		FILM NUMBER:		24503299

	BUSINESS ADDRESS:	
		STREET 1:		25 RECREATION PARK DR SUITE 108
		CITY:			HINGHAM
		STATE:			MA
		ZIP:			02043
		BUSINESS PHONE:		908-938-5561

	MAIL ADDRESS:	
		STREET 1:		25 RECREATION PARK DR SUITE 108
		CITY:			HINGHAM
		STATE:			MA
		ZIP:			02043

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	STEMCELLS INC
		DATE OF NAME CHANGE:	20000524

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	CYTOTHERAPEUTICS INC/DE
		DATE OF NAME CHANGE:	19930328
</SEC-HEADER>
<DOCUMENT>
<TYPE>424B3
<SEQUENCE>1
<FILENAME>form424b3.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Filed
Pursuant to Rule 424(b)(3)</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Registration
No. 333-273207</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>PROSPECTUS
SUPPLEMENT</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(To
Prospectus dated July 17, 2023)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><IMG SRC="form424b3_001.jpg" ALT="https:||www.sec.gov|Archives|edgar|data|883975|000149315222029423|form424b5_001.jpg" STYLE="height: 110px; width: 300px"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>2,281,626
Shares of Common Stock</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
that certain prospectus, dated July 17, 2023 (the &ldquo;Prospectus&rdquo;), filed on July 18, 2023 pursuant to Rule 424(b)(3), as part
of our registration statement on Form S-1 (File No. 333-273207), as amended on July 14, 2023 and declared effective on July 17, 2023,
under which Microbot Medical Inc. (the &ldquo;Company&rdquo;) registered for resale, from time to time, by the selling stockholders of
2,281,626 shares of the Company&rsquo;s common stock, par value $0.01 per share (&ldquo;Common Stock&rdquo;), underlying (i) Series A
preferred investment options and Series B preferred investment options issued by the Company pursuant to a securities purchase agreement,
dated October 21, 2022, that was entered into by the Company and certain of the selling stockholders, as amended on May 24, 2023, (ii)
Series C preferred investment options pursuant to a securities purchase agreement, dated June 2, 2023, that was entered into by the Company
and certain of the selling stockholders, (iii) Series D preferred investment options pursuant to a securities purchase agreement, dated
June 26, 2023, that was entered into by the Company and certain of the selling stockholders, and (iv) placement agent preferred investment
options issued by the Company pursuant to engagement letters dated October 3, 2022 and May 16, 2023, that were entered into by the Company
and H.C. Wainwright &amp; Co., LLC.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
prospectus supplement modifies, supersedes and supplements certain information contained or incorporated by reference in the Prospectus.
This prospectus supplement should be read in conjunction with the Prospectus, which is to be delivered with this prospectus supplement.
If there is any inconsistency between the information in the Prospectus and this prospectus supplement, you should rely on the information
in this prospectus supplement. This prospectus supplement is not complete without and may only be delivered or utilized in connection
with the Prospectus, including any future amendments or supplements to it. You should read the entire Prospectus and any amendments or
supplements carefully before you make an investment decision.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
Common Stock is listed on The Nasdaq Capital Market under the symbol &ldquo;MBOT.&rdquo; The last reported sale price of our Common Stock
on December 28, 2023 was $2.05 per share.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Investing
in our Common Stock is highly speculative and involves a significant degree of risk. Please consider carefully the specific factors set
forth under &ldquo;Risk Factors&rdquo; beginning on page 11 of the Prospectus and in our filings with the Securities and Exchange Commission.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Neither
the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or determined
if this prospectus is truthful or complete. Any representation to the contrary is a criminal offense.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>PREFERRED
INVESTMENT OPTION INDUCEMENT TRANSACTION</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Company entered into a Preferred Investment Option
Exercise and Inducement Letter on December 29, 2023 (the &ldquo;Inducement Letter&rdquo;) with certain selling stockholders (the &ldquo;Stockholders&rdquo;),
the registered holders of existing (i) Series A preferred investment options to purchase shares of the Company&rsquo;s Common Stock at
an exercise price of $2.20 per share, issued on October 25, 2022, as amended on May 24, 2023, (ii) Series C preferred investment options
to purchase shares of the Company&rsquo;s Common Stock at an exercise price of $2.075 per share, issued on June 6, 2023, and (iii) Series
D preferred investment options to purchase shares of the Company&rsquo;s Common Stock at an exercise price of $3.19 per share issued
on June 26, 2023 (the &ldquo;Existing Investment Options&rdquo;), pursuant to which the Stockholders agreed to exercise for cash their
Existing Investment Options to purchase an aggregate of 1,685,682 shares of the Company&rsquo;s Common Stock, at a reduced exercised
price of $1.62 per share, in consideration for the Company&rsquo;s agreement to issue new preferred investment option (the &ldquo;Inducement
Investment Option&rdquo;) to purchase up to an aggregate of 1,685,682 shares of the Company&rsquo;s Common Stock at an exercise price
of $1.50 per share. The Inducement Investment Options will be immediately exercisable from the date of issuance until five and one-half
(5.5) years following the date of issuance. No other changes to the Existing Investment Options were made.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
issuance of the Inducement Investment Options and the underlying shares of Common Stock are not being registered under the Securities
Act of 1933, as amended (the &ldquo;Securities Act&rdquo;), are not being offered pursuant to the Prospectus or this Supplement and are
being offered pursuant to a private placement under Section 4(a)(2) of the Securities Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
prospectus supplement is being filed to update the information in the Prospectus with the information summarized above.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
date of this prospectus supplement is December 29, 2023.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 2; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>form424b3_001.jpg
<TEXT>
begin 644 form424b3_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !N 2P# 2(  A$! Q$!_\0
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M@<BNVG6IU5>#N<%2A5I.U2-B:BD!S2UJ9A1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 E8OB>V:YT"Z5>2%W
M?3FMJHYD$D3(PR&&#6=6/-!Q[E4Y\DU+L>)BNF\#P12ZS*[J&:./*Y['I40\
M.QV<UW/J+M%902$*!]Z3/0"KVC:SH-GJ ,-K+;EQL\QFR#GU%?.X:A[*M&51
MI:]?N/J,7B?;4)1I)O3==#T  8%*1348,H*G((R"*?7TQ\J-VC%5[BRM[I"D
MT,<BGLR@U:I.M2TGHQJ36J.6U#P3IURI:V+6S_[/*_E7/OHGB#0G,ME(TD8[
MQ'/YJ:](Q01Q7)4P5.3O'W7W6AUT\?6BK2]Y=GJ<-8>.BC"+5+<HPX+IV^HK
MK++4;6_C#VLZ2*>N#R/PJ+4=$T_4D/VFV0M_?7AOTKE+SP9>V#FXTFY8XY"9
MPWX&HOB*&_OK\36V$K[>Y+[U_P  [SUI?2N"L_%]_ITHMM9MWP.-VW#?X&NN
MT_5[+4H]UK<*_JO0C\*WI8FG4T3L^S.>OA*M'5JZ[K5&C13=W/6E!KI.86C-
M%4-9F>WT>\GB;;(D3%6]#0!>S0#FO%/^$Q\0%#_Q,Y,_[J_X5ZKX;N9KWP_9
M7%Q(7FD3+,1R?RH UZ*** "BBB@ HHHH **** "BBB@ HHHH **BGGCMX7FD
M8+'&I9F/8#K6./&'A_'_ "$XOR/^% &[163<>(-+M;&.\EO(UAE&8SW?Z#J:
MS4\>Z \@3[4ZY.-S1G% '445#!<0W4"SPRI)$W*LIR#6-?\ C'1-.G,,UX&D
M'41*7Q]<4 ;](?NUS]GXST.^E$<5YL<\ 2J5S^)K?!# $'(/(Q0!R?CBTGGT
MJ*6)2RQ2;G"CMCK^%>>QH\\J11*7=C@ =37L>H7UII]J9KV58X<A2S=.:Q8=
M>\*PR[X+FU21CC*I@_RKS,3E_MJG.I6[GJ83,G0HNERWWM\S;TV)X-.MXI#E
MTC ;ZU;IJD%01TQD&AF"*68@*.237I15DD>8W=ML?17.7OC;0[&5HVN_-<=1
M$I;'X]*KP_$#09FVF::+W>,X_2F(ZNBH8+B*Y@6>&19(F&5<'@BLAO%VA)(R
M-J40=201@\$?A0!NTA&:SH-<TZZL9+V*[C-M&</+T /XUDMX^T!9/+%S(QSC
M<L9QF@#<N]/M;^$QW,*2K_M"N1O_  7+;2_:-'N'C=>0A/(^AKM$8.@(.00"
M#Z@U0U+6]-TE?],O$C8]$SEOR'-<]7#4ZFK6O?J;T<35HOW7I^'W'+VGBS4-
M+F^SZU;.<<!P,'_ UUMCJEKJ$(DMIE<'J >1]17,7WC7PS>(8;B.6=.Q\GC]
M:PTBTZ:<3^'=6\N?.1!*2A;V!K"U>A_>C^)T-X?$=.27X?\  /4 >*S]>/\
MQ(+_ /ZX-_*N<L?%\UI-]EUJW:)\X$H''X_XUN:K<PW7AJ^EAE61&@8Y4Y[5
MTTZ\*FD7KVZG-5P]2E\2T[K8\1_AKVSPC_R*VG_]<Z\3'W/PKUW1-7L=(\'Z
M=+>W"Q*8N >IY["MC ZNBN07XAZ$9=I>XQ_>\OC_ !K?TW6+#5H]]E=)+CJ
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MDEC?SVDH(DBD*D>OH?RKWN,?N4'0A0#[<5RWBSP@NN#[5:%8[U1@YZ2#T/\
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M_</TKV[Q5#+<>&;V*"-I)&0;57J>17DA\/:R4(_LRYZ?\\S0![/HG_(#L/\
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)A5'0"GT ?__9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
